CA2511013A1 - Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques - Google Patents

Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques Download PDF

Info

Publication number
CA2511013A1
CA2511013A1 CA002511013A CA2511013A CA2511013A1 CA 2511013 A1 CA2511013 A1 CA 2511013A1 CA 002511013 A CA002511013 A CA 002511013A CA 2511013 A CA2511013 A CA 2511013A CA 2511013 A1 CA2511013 A1 CA 2511013A1
Authority
CA
Canada
Prior art keywords
ser
antibody
val
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002511013A
Other languages
English (en)
Inventor
Ellen Garber
Veronique Bailly
Jeffrey L. Browning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2511013A1 publication Critical patent/CA2511013A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des structures d'anticorps multivalents spécifiques au récepteur bêta de lymphotoxine humaine ainsi que leur utilisation dans le traitement du cancer et l'inhibition de l'augmentation du volume des tumeurs chez un sujet.
CA002511013A 2002-12-20 2003-12-22 Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques Abandoned CA2511013A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43515402P 2002-12-20 2002-12-20
US60/435,154 2002-12-20
PCT/US2003/041393 WO2004058191A2 (fr) 2002-12-20 2003-12-22 Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques

Publications (1)

Publication Number Publication Date
CA2511013A1 true CA2511013A1 (fr) 2004-07-15

Family

ID=32682169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002511013A Abandoned CA2511013A1 (fr) 2002-12-20 2003-12-22 Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques

Country Status (8)

Country Link
US (1) US20060104971A1 (fr)
EP (1) EP1583503A4 (fr)
JP (1) JP2006515750A (fr)
CN (1) CN100473664C (fr)
AU (1) AU2003299984A1 (fr)
CA (1) CA2511013A1 (fr)
NO (1) NO20053530L (fr)
WO (1) WO2004058191A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
GEP20063752B (en) * 2000-10-13 2006-02-27 Biogen Inc Humanized Anti-LT-Beta-R Antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2004002431A2 (fr) * 2002-07-01 2004-01-08 Biogen, Inc. Anticorps humanises diriges contre le recepteur de la lymphotoxine beta
WO2004003144A2 (fr) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Anticorps qui se lient specifiquement a reg iv
MXPA05006663A (es) * 2002-12-20 2005-09-30 Biogen Idec Inc Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos.
WO2005000898A2 (fr) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Purification et synthese preferentielle de molecules de liaison
CA2560742A1 (fr) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Agents de couplage recepteurs et leurs applications therapeutiques
WO2006074399A2 (fr) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Molecules de liaison multispecifiques comprenant des peptides de connexion
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
AU2007227292B2 (en) 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
AU2014200661B2 (en) * 2006-06-12 2016-06-30 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
AU2016231617B2 (en) * 2006-06-12 2018-08-23 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
EP2418223A3 (fr) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Protéines de liaison polyvalente à chaîne unique avec une fonction effectrice
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
SG154441A1 (en) * 2006-10-20 2009-08-28 Biogen Idec Inc Treatment of demyelinating disorders
BRPI0814060A2 (pt) * 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
AU2008282218A1 (en) * 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
KR100967623B1 (ko) * 2008-02-22 2010-07-05 전남대학교산학협력단 림포톡신을 포함하는 자궁경부암 예방 또는 치료용 조성물
DK2132228T3 (da) 2008-04-11 2011-10-10 Emergent Product Dev Seattle CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
JP6211597B2 (ja) * 2012-05-01 2017-10-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規抗体
EP2950788B1 (fr) * 2013-02-04 2019-01-09 University Of Huddersfield Composition comprenant un agoniste de tnfr et au moins un inhibiteur de thiorédoxine destiné à être utilisé dans le traitement d'un carcinome
TWI700295B (zh) 2013-12-16 2020-08-01 馬來西亞商Ｍａｂ探索私人有限公司 對會感染人類之腸病毒具有專一性之抗體
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
WO2017062604A1 (fr) 2015-10-06 2017-04-13 Regents Of The University Of Minnesota Composés thérapeutiques et procédés
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022117569A1 (fr) 2020-12-02 2022-06-09 Oncurious Nv Anticorps antagoniste de ccr8 en combinaison avec un anticorps agoniste du récepteur bêta de la lymphotoxine en thérapie contre le cancer
WO2023198848A1 (fr) 2022-04-13 2023-10-19 Vib Vzw Agoniste de ltbr utilisé en polythérapie contre le cancer
WO2023218320A1 (fr) * 2022-05-11 2023-11-16 Pfizer Inc. Anticorps anti-récepteur de la lymphotoxine bêta et leurs procédés d'utilisation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US669941A (en) * 1898-12-17 1901-03-12 Electric Axle Light & Power Company Electric switch.
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE397665T1 (de) * 1992-12-04 2008-06-15 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
EP0809510B1 (fr) * 1995-01-26 2004-06-09 Biogen, Inc. Complexes de lymphotoxine-alpha/beta et anticorps de recepteur anti-lymphotoxine-beta utiles en tant qu'agents anti-tumoraux
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
EP1272647B1 (fr) * 2000-04-11 2014-11-12 Genentech, Inc. Anticorps multivalents et leurs utilisations
AU7967801A (en) * 2000-06-30 2002-01-14 Innogenetics Nv Differential diagnosis of neurological diseases
JP2004520810A (ja) * 2000-08-24 2004-07-15 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
GEP20063752B (en) * 2000-10-13 2006-02-27 Biogen Inc Humanized Anti-LT-Beta-R Antibodies
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7642242B2 (en) * 2002-03-05 2010-01-05 Genentech, Inc. PRO34128 polypeptides
WO2004002431A2 (fr) * 2002-07-01 2004-01-08 Biogen, Inc. Anticorps humanises diriges contre le recepteur de la lymphotoxine beta
MXPA05006663A (es) * 2002-12-20 2005-09-30 Biogen Idec Inc Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos.

Also Published As

Publication number Publication date
WO2004058191A3 (fr) 2005-12-29
CN1798765A (zh) 2006-07-05
JP2006515750A (ja) 2006-06-08
AU2003299984A1 (en) 2004-07-22
CN100473664C (zh) 2009-04-01
NO20053530D0 (no) 2005-07-19
US20060104971A1 (en) 2006-05-18
NO20053530L (no) 2005-09-20
EP1583503A4 (fr) 2006-08-09
WO2004058191A2 (fr) 2004-07-15
EP1583503A2 (fr) 2005-10-12

Similar Documents

Publication Publication Date Title
CA2511013A1 (fr) Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques
AU2020203365B2 (en) CD33 antibodies and use of same to treat cancer
RU2755503C2 (ru) Анти-lag-3 антитела и их композиции
CN107922496B (zh) IL2Rβ/通用γ链抗体
KR20220110224A (ko) Bcma에 결합하는 항체 및 이의 용도
KR20060132006A (ko) 수용체 커플링제 및 이의 치료적 용도
EP2021370B1 (fr) Agents de liaison du récepteur trail et leurs utilisations
CN110799540B (zh) 多特异性抗体及其制备和使用方法
KR20050094819A (ko) 화학요법제와 조합된 림프독소 베타 수용체 약제
CN110831973B (zh) 多特异性抗体及其制备和使用方法
KR20160044043A (ko) Gitr 항원 결합 단백질
JP2006515750A5 (fr)
CN110396129B (zh) 人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用
EP2074148A1 (fr) Nouveaux anticorps anti-prolifération
CN114685660A (zh) 抗cldn18.2抗体及其制备方法和应用
KR20170082495A (ko) 암 치료용 항-ck8 항체
CN106795223A (zh) 针对Fcγ受体IIB及Fcε受体的新型抗体
KR20200123169A (ko) B7-h4 항체 투약 섭생법
KR20220160555A (ko) Cd40에 결합하는 항체 및 이의 용도
KR20160131082A (ko) Lg1-3에 특이적인 항-라미닌4 항체
KR20200108870A (ko) Tim3에 대한 항체 및 그의 용도
CN112175087B (zh) 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
RU2761638C1 (ru) Антитела против лиганда программируемой смерти (pd-l1) и их применение
AU2021403263A1 (en) Bispecific antibody for specifically neutralizing tgf-β signal of helper t cell, and pharmaceutical combination and use thereof
RU2811477C2 (ru) Мультиспецифические антитела и способы их получения и применения

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued